IP Library Granted Patent US 11,884,929
Granted Patent B2
US 11,884,929 · App. 16/880,583 · Granted Jan 30, 2024

CPMV enhancer elements

Inventors: Pierre-Olivier Lavoie (Quebec, CA); Marc-Andre D'Aoust (Quebec, CA)
Assignee: Medicago Inc.
C12N15/8216C12N7/045C12N15/8251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,929
App. No.
16/880,583
Granted
Jan 30, 2024
Kind
B2
Abstract

An expression enhancer comprising a CPMV 5′UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3′ end of the 5′UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences. Plants comprising the expression enhancer and methods using the expression enhancer are also described

Claims (36)

1. A nucleic acid molecule comprising:

a first portion consisting of nucleotides 1-160 of SEQ ID NO:1 having a substitution of G115A,

a second portion comprising a plant Kozak sequence, a multiple cloning site, or a combination of a plant Kozak sequence and a multiple cloning site, the second portion positioned 3′ to the first portion, and

a third portion encoding a heterologous protein of interest, the third portion positioned 3′ to the second portion,

wherein the nucleic acid molecule does not comprise nucleotides 161-509of SEQ ID NO:4.

2. The nucleic acid molecule of claim 1 , wherein the second portion is a multiple cloning site.

3. The nucleic acid molecule of claim 1 , wherein the second portion is a plant Kozak sequence.

4. The nucleic acid molecule of claim 1 , wherein the second portion is a multiple cloning site and a plant Kozak sequence, wherein the multiple cloning site is positioned 3′ to the first portion and the plant Kozak sequence is positioned 3′ to the multiple cloning site.

5. The nucleic acid molecule of claim 1 , wherein the plant Kozak sequence is selected from the group consisting of:

caA(A/C)a;

aaA(A/C)a;

aa(A/G)(A/C)a;

AGAAA;

AGACA;

AGGAA;

AAAAA;

AAACA;

AAGCA;

AAGAA;

AAAGAA;

and

AAAGAA.

6. The nucleic acid molecule of claim 1 , wherein the first portion and the second portion together consist of the nucleotide sequence of SEQ ID NO: 2.

7. The nucleic acid molecule of claim 1 , wherein the first portion and the second portion together consist of the nucleotide sequence of SEQ ID NO: 75.

8. The nucleic acid molecule of claim 1 , wherein the heterologous protein of interest is a viral protein or an antibody.

9. The nucleic acid molecule of claim 8 , wherein the viral protein is an influenza hemagglutinin (HA) selected from the group consisting of H1, H2, H3, H4, H 5 , H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and influenza type B hemagglutinin.

10. The nucleic acid molecule of claim 9 , wherein the influenza hemagglutinin (HA) is a chimeric HA, wherein a native trans-membrane domain of the HA is replaced with a heterologous trans-membrane domain.

11. A plant expression system comprising the nucleic acid molecule of claim 1 or a vector comprising the nucleic acid molecule of claim 1 .

12. The plant expression system of claim 11 , further comprising a regulatory region operatively linked to the nucleic acid molecule of claim 1 .

13. The plant expression system of claim 12 , wherein the regulatory region is selected from the group a plastocyanin promoter, a CaMV 35S promoter, a 2x CaMV35S promoter, a CAS promoter, a RbcS promoter, a Ubi promoter, and an actin promoter.

14. The plant expression system of claim 11 , wherein the nucleic acid molecule or vector further comprises a comovirus 3′ UTR.

15. The plant expression system of claim 11 , wherein the nucleic acid molecule or vector further comprises a suppressor of silencing.

16. The plant expression system of claim 15 , wherein the suppressor of silencing is selected from the group HcPro and p19.

17. A method of producing a protein of interest in a plant or in a portion of a plant comprising, introducing into the plant or in the portion of a plant the plant expression system of claim 11 , and incubating the plant or the portion of a plant under conditions that permit expression of the heterologous protein of interest.

18. A plant or portion of a plant transiently transfected or stably transformed with the plant expression system of claim 11 .

19. The nucleic acid molecule of claim 1 , wherein the second portion further comprises a linker, a polylinker, a recombination site, or a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2024
From: MEDICAGO INC.
To: ARAMIS BIOTECHNOLOGIES INC.
Reel/Frame 069383/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2021
From: LAVOIE, PIERRE-OLIVIER; D'AOUST, MARC-ANDRE
To: MEDICAGO INC.
Reel/Frame 054967/0913 →
Continuity (4)
Continuation 15110696
Continuation In Part PCTCA2014050326 · Mar 28, 2014
Provisional Application 61925852 · Jan 10, 2014
Related Publication 20200283784A1 · Sep 10, 2020